Vemurafenib in melanoma with BRAF V600E mutation - PubMed (original) (raw)
Comment
. 2011 Oct 13;365(15):1448; author reply 1450.
doi: 10.1056/NEJMc1108651.
- PMID: 21995398
- DOI: 10.1056/NEJMc1108651
Comment
Vemurafenib in melanoma with BRAF V600E mutation
Hiroyuki Morita et al. N Engl J Med. 2011.
No abstract available
Comment on
- Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA; BRIM-3 Study Group. Chapman PB, et al. N Engl J Med. 2011 Jun 30;364(26):2507-16. doi: 10.1056/NEJMoa1103782. Epub 2011 Jun 5. N Engl J Med. 2011. PMID: 21639808 Free PMC article. Clinical Trial.
Similar articles
- Vemurafenib in melanoma with BRAF V600E mutation.
Lott JP. Lott JP. N Engl J Med. 2011 Oct 13;365(15):1449-50; author reply 1450. doi: 10.1056/NEJMc1108651. N Engl J Med. 2011. PMID: 21995400 No abstract available. - Vemurafenib in melanoma with BRAF V600E mutation.
Dalle S, Poulalhon N, Thomas L. Dalle S, et al. N Engl J Med. 2011 Oct 13;365(15):1448-9; author reply 1450. doi: 10.1056/NEJMc1108651. N Engl J Med. 2011. PMID: 21995399 No abstract available. - Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA; BRIM-3 Study Group. Chapman PB, et al. N Engl J Med. 2011 Jun 30;364(26):2507-16. doi: 10.1056/NEJMoa1103782. Epub 2011 Jun 5. N Engl J Med. 2011. PMID: 21639808 Free PMC article. Clinical Trial. - Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
Ravnan MC, Matalka MS. Ravnan MC, et al. Clin Ther. 2012 Jul;34(7):1474-86. doi: 10.1016/j.clinthera.2012.06.009. Epub 2012 Jun 27. Clin Ther. 2012. PMID: 22742884 Review. - Vemurafenib.
Garbe C, Abusaif S, Eigentler TK. Garbe C, et al. Recent Results Cancer Res. 2014;201:215-25. doi: 10.1007/978-3-642-54490-3_13. Recent Results Cancer Res. 2014. PMID: 24756795 Review.
Cited by
- Cutaneous Side Effects of Modern Targeted Therapy and Immunotherapy in Patients with Dermatological Malignancies.
Plachouri KM, Florou V, Georgiou V, Georgiou S. Plachouri KM, et al. Cancers (Basel). 2023 Jun 9;15(12):3126. doi: 10.3390/cancers15123126. Cancers (Basel). 2023. PMID: 37370736 Free PMC article. Review. - Molecular tumor board: the University of California-San Diego Moores Cancer Center experience.
Schwaederle M, Parker BA, Schwab RB, Fanta PT, Boles SG, Daniels GA, Bazhenova LA, Subramanian R, Coutinho AC, Ojeda-Fournier H, Datnow B, Webster NJ, Lippman SM, Kurzrock R. Schwaederle M, et al. Oncologist. 2014 Jun;19(6):631-6. doi: 10.1634/theoncologist.2013-0405. Epub 2014 May 5. Oncologist. 2014. PMID: 24797821 Free PMC article. - Advances in the management of low-grade gliomas.
Nageswara Rao AA, Packer RJ. Nageswara Rao AA, et al. Curr Oncol Rep. 2014;16(8):398. doi: 10.1007/s11912-014-0398-9. Curr Oncol Rep. 2014. PMID: 24925153 Review. - An evaluation of regulatory and commercial barriers to stratified medicine development and adoption.
Meadows NA, Morrison A, Brindley DA, Schuh A, Barker RW. Meadows NA, et al. Pharmacogenomics J. 2015 Feb;15(1):6-12. doi: 10.1038/tpj.2014.51. Epub 2014 Oct 7. Pharmacogenomics J. 2015. PMID: 25287070 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials